Microbiota Transfer Therapy (MTT) Trial

Arizona State University, Dr. James Adams

Following the success of our first Microbiota Transfer Therapy (MTT) Trial, the next Phase 2 study of the MTT is nearing completion. This next phase uses a liquid formulation rather than capsules, and early feedback from participating families is encouraging—many report reduced pain and additional positive changes. The research team at ASU has since launched a company, Gut Brain Axis, with the goal of bringing this biologic treatment to market. Pending results, the team hopes to seek FDA approval for Pitt Hopkins Syndrome, marking a major step forward for our community.

Apply for Clinical Trial here.

Read more about ASU’s MTT here.